Utility of pneumococcal vaccine among elderly population in buraidah primary health care centers

Sulaiman A. Alawaji, Chandra S. Kalevaru


Background: People with chronic diseases tend to land up with high mortality and morbidity. Objective of the study is to determine the prevalence of Pneumococcal vaccine utility among the 50 years and above age group population, to find the demographic profile, the knowledge of PCV among the general population.

Methods: A cross-sectional study was conducted randomly in 6 primary health care centers in Buraidah city, Saudi Arabia from the aged 50 years and above population. Sample size was calculated by using WHO statistical software for sample size determination, the result of sample size was 236 participants. A interview-based questionnaire was used after obtaining consent from each participant. Data entered and analyzed using the SPSS software 21.0 version. For categorical analysis, chi square test was applied.

Results: In the present study, a total of 202 samples of the population has participated and response rate was 86%. About only 12.9% (26/202) of study population taken PCV vaccine in the study. About 79.7% were having different chronic diseases. About 83.7% were given a response as PCV prevents the disease. There was statistically significant association was observed between different levels of education and chronic heart disease with PCV vaccination status (p<0.05).

Conclusions: Based on the study results, Pneumococcal vaccination coverage was low, in comparison with Riyadh study in 2018; our study vaccination coverage was more. Still need Health promotional measures among the general public to increase the coverage of PCV.


PHCC, Pneumococcal vaccine, Knowledge, Chronic disease

Full Text:



World health organization. 23-valent pneumococcal polysaccharide vaccine: WHO position paper Vaccine antipneumococcique polyosidique 23-valent: note de synthèse de l'OMS. weekly epidemiological record. Relevé épidémiologique hebdomadaire. 2008;83(42):373-84.

Alharbi NS, Al-Barrak AM, Al-Moamary MS, Zeitouni MO, Idrees MM, Al-Ghobain MO, et al. The Saudi thoracic society pneumococcal vaccination guidelines-2016. Ann Thoracic Med. 2016;11(2):93.

Asghar AH. Frequency and antibiotic susceptibility of gram-positive bacteria in Makkah hospitals. Ann Saudi Med. 2011;31(5):462-8.

Musher DM. How effective is vaccination in preventing pneumococcal disease?. Infect Dis Clin. 2013;27(1):229-41.

El-Mouzan MI, Twan-Danso K, Al-Awamy BH, Niazi GA, Altorki MT. Pneumococcal infections in eastern Saudi Arabia: serotypes and antibiotic sensitivity patterns. Trop Geo Med. 1988;40(3):213-7.

Kambal AM, Abdullah AM. Childhood pneumococcal bacteraemia in Riyadh, Saudi Arabia. Ann Tropical Paediatr. 1997;17(3):245-51.

Yezli S, Shibl AM, Livermore DM, Memish ZA. Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia. J Chemother. 2012;24(3):125-36.

Song JY, Cheong HJ, Heo JY, Noh JY, Seo YB, Kim IS, et al. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J. 2013;54(2):469-75.

Gautret P, Bauge M, Simon F, Benkouiten S, Parola P, Brouqui P. Pneumococcal vaccination and Hajj. Int J Infect Dis. 2011;15(10):e730.

Al-Rashed RS. Pattern of admission to hospitals during muslim pilgrimage (Hajj). Saudi Med J. 2003;24(10):1073-6.

Almusalam YA, Ghorab MK, Alanezi SL. Prevalence of influenza and pneumococcal vaccine uptake in Saudi type 2 diabetic individuals. J Family Med Prim Care. 2019;8(6):2112.

Centers for Disease Control and Prevention (CDC. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. Morbidity and mortality weekly report. 2012;61(21):394-5.

Immunization coverage. Available at: https://www. Accessed on 20 September 2021.

Cassimos DC, Effraimidou E, Medic S, Konstantinidis T, Theodoridou M, Maltezou HC. Vaccination programs for adults in Europe. Vaccines. 2020;8(1):34.

Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Vaccines. 2021;9(2):34.

Sözen M, Karatoprak AP, Demirhan Y, Nasırlıer GÇ, Selek A, Gezer E, et al. Awareness of influenza and pneumococcal vaccines in diabetic patients. J Diab Metab Disord. 2021;7:1-7.

Yeşilova A, Bilge M, Özsoy N, Adaş M. Evaluation of influenza, pneumococcus, zoster, measles, diphtheria, and pertussis vaccination rates in patients with type 1 and type 2 diabetes mellitus; a single-center experience from turkey. Turkish J Endocrinol Metab. 2021;25(1):45-9.

Alqahtani AS, Bondagji DM, Alshehari AA, Basyouni MH, Alhawassi TM, BinDhim NF, et al. Vaccinations against respiratory infections in Arabian Gulf countries: Barriers and motivators. World J Clin Cases. 2017;5(6):212.

Thewjitcharoen Y, Butadej S, Malidaeng A, Yenseung N, Nakasatien S, Lekpittaya N, et al. Trends in influenza and pneumococcal vaccine coverage in Thai patients with type 2 diabetes mellitus 2010-2018: Experience from a tertiary diabetes center in Bangkok. J Clin Translat Endocrinol. 2020; 20:100227.

Sakamoto A, Chanyasanha C, Sujirarat D, Matsumoto N, Nakazato M. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan. BMC public health. 2018; 18(1):1-7.

Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850 000 individuals. Deutsches Ärzteblatt Int. 2013;110(44): 743.

Frank O, De Oliveira Bernardo C, González-Chica DA, Macartney K, Menzies R, et al. Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice. Human Vac Immunother. 2020;16(4):965-71.

Dullius CR, Zani L, Chatkin JM. Theoretical pneumococcal vaccine coverage: analysis of serotypes isolated from inpatients at a tertiary care hospital. J Brasileiro de Pneumol. 2018;44:361-6.